IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Oleg Iliich Epshtein

Title of Invention : Medicament and method for treating

pathological syndrome

Date Filed : January 22, 2005
Serial No. : 10/522,652
Examiner : Dr. Ilia Ouspenski

Art Unit : 1644

DECLARATION UNDER 37 CFR 1.132

I, O. I. Epshtein, Dr. Sc, do hereby declare as follows:

- 1. My name is Dr. Oleg I. Epstein (aka Epshtein). I am a widely recognized scientist in the fields of pharmacology and physiology. I authored over 100 articles in the peer-reviewed journals.
- 2. The company I lead, Materia Medica Holdings, successfully sells the product Anaferon covered by the above-identified application 10/522,652.
- 3. I am a named co-inventor of the '652 application. The other named co-inventors of the '652 application are Evgeny D. Goldberg and Alexander M Digay.
- 4. The invention relates to homeopathically activated (or "potentiated") form of antibodies to interferon.
- 5. It is my understanding that the claims of the '652 application were rejected over International Publication No. WO 01/97842 (International Patent Application No. PCT/RU01/00239), which was published on December 27, 2001.
- 6. I am a named co-inventor on the '239 application with Mark B. Shtark and Tamara M. Kolyadko.
- 7. I am aware that Example 39 of the '239 application (paragraphs 0345-0347 of U.S. Publication No. 2003/0099636] discloses potentiated antibodies to gamma-interferon.
- 8. I do hereby declare that the portion of the '239 application in par. 4 above, namely, Example 39 and the potentiated antibodies to interferon, were invented solely by me, without any participation of Mark B. Shtark and Tamara M. Kolyadko.

All statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment; or both, under Section 1001 of Title 18 of the U.S. Code and that such willful false statements may jeopardize the validity of any patent application issuing thereon.

Dated: February 15, 2009